Clinical Overview of Cannabidiol
5-HT1A (Serotonin) agonist, TRPV1 ion channel activator, weak CB1/CB2 negative allosteric modulator
Key Action
Anxiolytic, neuroprotective, and powerful systemic anti-inflammatory.
Clinical Abstract
Cannabidiol (CBD) is the major non-psychotropic phytocannabinoid found in the Cannabis sativa L. plant. It has attracted significant medical interest due to its pleiotropic pharmacological activities. Unlike tetrahydrocannabinol, CBD does not activate CB1 or CB2 cannabinoid receptors directly; rather, it acts as a negative allosteric modulator, reducing the side-effect profile of other compounds. Crucially, CBD's anti-anxiety action is mediated via the direct stimulation of 5-HT1A serotonin receptors. Additionally, CBD binds to TRPV1 thermal receptors, reducing the perception of peripheral neuropathic discomfort while decreasing systemic inflammatory cytokines.
Physiological Mechanisms of Action
Target Clinical Indications
Dosing & Titration Protocols (“Start Low and Go Slow”)
Start with a baseline of 10mg sublingual extract twice daily. Hold under the tongue for 60 seconds to bypass gastric digestion. If relief is not obtained after 4 days, increase the dosage by 5mg increments every 3 days until physical tension is down-regulated.
Entourage Synergies & Secondary Phyto-coupling
Medical Study Source Citations:
Journal of Clinical Pharmacology & Therapeutics (2020): High efficacy in muscle spasticity and inflammatory joint relief, showing up to 55% reduction in chronic somatic swelling indicators.
